First Step to Final Offer 4/7/26

CAREER OPPORTUNITIES

Class of 2028 Finance and Consulting Opportunities

• Mesirow Investment Banking Summer Analyst 2027 Link

• Goldman Sachs 2027 | Americas | Dallas Metro Area | Asset Management, Alternatives / Private Investing | Summer Analyst Link

• Jefferies 2027 Investment Banking Summer Analyst Program – New York, Israel Coverage Group Link

• Guggenheim Partners Finance Intern Link

• Citi Banking Summer Analyst - Multiple Roles and Locations Link

• Bridgewater Associates 2027 Investment Associate Intern Link

• Scotiabank 2027 Summer Analyst - New York - Multiple Roles Link

• Nomura Securities International 2027 Investment Management Summer Analyst Program Link

• SIG Analyst Internship: Summer 2027 - Multiple Roles and Locations Link

To see c/o 2028 opportunities, click here: Class of 2028 Application Tracker

Class of 2027 Finance and Consulting Opportunities

• Insight Partners 2027 Full Time Investment Analyst Link

• Financial Technology Partners 2026 Summer Analyst - Multiple Roles and Locations Link

• Maven Securities Ltd Trader Summer Internship Chicago 2026 Link

• Alvarez & Marsal Intern Summer 2026, Global Transaction Advisory Group – Financial Due Diligence Link

  
  To see c/o 2027 opportunities, click here: Class of 2027 Application Tracker

Class of 2026 Finance Opportunities

• Nomura Securities International 2026 Global Markets Full-Time Analyst Program - New York - Multiple Roles Link

TECHNICAL QUESTION OF THE WEEK:

MARKET NEWS

Goldman Sachs Sees Systematic Funds Turning Net Buyers After Selloff

Systematic or “fast-money” investors, including trend-following and volatility-targeting funds, could shift back to buying equities after sharply reducing exposure during the recent market downturn. Goldman Sachs estimates these funds sold around $240 billion in global stocks over the past month but may purchase roughly $55 billion in the coming month, with about $20 billion directed toward US equities. However, buying is expected to be gradual, limiting any immediate market impact.

The outlook depends heavily on market performance. A rebound in the S&P 500 could accelerate inflows significantly, while further declines may trigger additional selling. Key technical levels are also being closely watched, as a move into certain ranges could prompt stronger buying from trend-driven strategies, potentially signaling a turning point in the recent selloff.

Source: Bloomberg

M&A DEAL OVERVIEW

Neurocrine Acquires Soleno Therapeutics in $2.9 Billion Deal

Neurocrine Biosciences is set to purchase rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, marking the neuroscience company's entry into metabolic disorders. The acquisition centers on Vykat XR, the first U.S.-approved treatment for hyperphagia linked to Prader-Willi syndrome — a rare genetic condition causing extreme, persistent hunger that can lead to severe obesity and behavioral complications. Neurocrine offered $53 per Soleno share, representing a roughly 34% premium, sending Soleno's stock up nearly 33% on the announcement. Vykat XR generated approximately $190 million in sales within its first nine months on the market, and analysts at Cantor project it could surpass $1 billion in annual sales by 2029. CEO Kyle Gano described the drug as a potential blockbuster, though noted the company is focused on the U.S. market for now with no immediate European launch plans. The deal is expected to close within 90 days and will be funded primarily through cash on hand alongside a modest amount of prepayable debt.

Source: Reuters

LAST WEEK TECHNICAL QUESTION OF THE WEEK ANSWER: